Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF ...

Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3% on Wednesday following the announcement that the company obtained 510(k) ...

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Study findings published in the Annals of Family Medicine show high diagnostic performance of these technologies ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...

The US Food and Drug Administration has approved the use of finerenone (Kerendia) in heart failure (HF) patients with mildly ...